Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Correlation of values for Conners' Continuous Performance Test 3rd Edition (CPT-3) scores (d' T-score, Commission Errors, Omission Errors, and Reaction Time) with AD disease severity based on Eczema Area and Severity Index (EASI)

Part A Conner's CPT-3 d' T-scoring as stated above. EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, apulation, edema\], scratching \[excoriation\], and lichenification) will each be assessed for severity by the investigator or designee on a scale of 0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6.

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Body Surface Area (BSA)

Part A Conner's CPT-3 d' T-scoring as stated above. BSA affected by AD is assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and will be reported as a percentage of all major body sections combined.

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Peak Pruritus Numeric Rating Scale (NRS)

Part A Conner's CPT-3 d' T-scoring as stated above. Peak Pruritus NRS is a simple assessment tool that patients will use to report the average intensity of their pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Skin Pain Numeric Rating Scale (SP-NRS)

Part A Conner's CPT-3 d' T-scoring as stated above. SP-NRS is a validated, self-administered PRO measuring the skin pain severity at its worst with a recall period of 24 hours pain severity in adults and adolescents. This single-item questionnaire uses an 11-point scale, which ranges from "0-No pain" to "10-Worst pain possible." Skin pain severity based on SP-NRS can be categorized as: clear (0), mild (1-3), moderate (5-6), severe (7-9), and very severe (10).

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Patient-Reported Outcomes Measurement Information System Pediatric Sleep Disturbance Questionnaire (PROMIS Pediatric Sleep Disturbance)

Part A Conner's CPT-3 d' T-scoring as stated above. PROMIS sleep disturbance questionnaire is used to measure self-reported perceptions of sleep quality, sleep depth, and restoration. This includes perceived difficulties getting to sleep and staying asleep, as well as sleep satisfaction. Parent-reported sleep.

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Children's Dermatology Life Quality Index (CDLQI)

Part A Conner's CPT-3 d' T-scoring as stated above. CDLQI is a validated questionnaire designed to measure the impact of skin disease on the quality of life (QoL) in children over a recall period of the past week. 9 of the 10 questions are scored by (0) Not answered/not at all, (1) only a little, (2) quite a lot to (3) very much. Question 7 has a possible response of (3) prevented school. The sum of the score of each question has a maximum of 30 and a minimum of 0. The higher the score the greater the impact on QoL. CDLQI can be a percentage of the maximum possible score of 30.

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Hospital Anxiety and Depression Scale (HADS)

Part A Conner's CPT-3 d' T-scoring as stated above. HADS is an instrument for screening anxiety and depression in non-psychiatric populations; repeated administration also provides information about changes in a patient's emotional state. HADS consists of 14 items, 7 each for anxiety and depression symptoms; possible scores range from 0 to 21 for each subscale. The following cut-off scores are recommended for both subscales: 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.

Time frame: Day 1

Correlation of values for Conners' CPT-3 scores with AD disease severity based on Investigator's Global Assessment (IGA)

Part A Conner's CPT-3 d' T-scoring as stated above. IGA is an instrument used for rapid and easy assessment of atopic dermatitis disease lesional severity globally based on a 5-point scale with range from 0-4, (0 = Clear, 1 = Almost clear, 2 = Mild disease, 3 = Moderate disease and 4 = Severe disease).

Time frame: Day 1

Correlation of values for Adult/Adolescent Sensory Profile (AASP) Sensory Sensitivity Score with AD disease severity based on EASI

Part A AASP is a 60-item self-report questionnaire measuring sensory responsiveness patterns in six different sensory modalities, including taste/smell, movement, visual, touch, activity and auditory processing. Patients complete the AASP by responding to each item with a five-point Likert scale (1 = almost never, 2 = seldom, 3 =occasionally, 4 = frequently, or 5 = always). Higher scores in each quadrant represented stronger preference to adopt certain types of sensory responsiveness patterns. The quadrant score can be categorized into one of the 5 categories, indicating how a particular patient's score compares to people in the same age group (adolescents of age 11-17 years) without disabilities: much less than most people, less than most people, similar to most people, more than most people, much more than most people. EASI measuring as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on BSA

Part A AASP scoring as stated above. BSA scoring as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on Peak Pruritus NRS

Part A AASP scoring as stated above. Peak Pruritus NRS scaling as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on SP-NRS

Part A AASP scoring as stated above. SP-NRS scaling as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on PROMIS Pediatric Sleep Disturbance Questionnaire

Part A AASP scoring as stated above. PROMIS Pediatric sleep disturbance scaling as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on CDLQI

Part A AASP scoring as stated above. CDLQI scoring as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on HADS

Part A AASP scoring as stated above. HADS scoring as stated above.

Time frame: Day 1

Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on IGA

Part A AASP scoring as stated above. IGA scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on EASI

Part A Stroop Color and Word Test (SCWT) is a test used to measure selective inhibition, the ability to attend to certain environmental stimuli while inhibiting other stimuli. Stroop Interference scores are calculated from the number of correctly identified items in the three trials. Higher Stroop Interference scores represent poorer performance and suggests impaired executive functioning. EASI scoring as stated above.

Time frame: Day 1

Correlation of values for SCWT Interference Score with AD disease severity based on BSA

Part A SCWT scoring as stated above. BSA scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on Peak Pruritus NRS

PART A SCWT scoring as stated above. Peak Pruritus NRS scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on SP-NRS

Part A SCWT scoring as stated above. SP-NRS scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on PROMIS Pediatric Sleep Disturbance Questionnaire

Part A SCWT scoring as stated above. PROMIS scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on CDLQI

Part A SCWT scoring as stated above. CDLQI scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on HADS

Part A SCWT scoring as stated above. HADS scoring as stated above.

Time frame: Day 1

Correlation of values for Stroop Interference Score with AD disease severity based on IGA

Part A SCWT scoring as stated above. IGA scoring as stated above.

Time frame: Day 1

Determine the appropriate minimal Conners' CPT-3 d-prime T score

Used as an entrance criterion into Part B

Time frame: Day 1

Correlation of change in AD disease severity based on EASI with change in Conners' CPT-3 score

Part B EASI scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on BSA with change in Conners' CPT-3 score

Part B BSA scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on Peak Pruritus NRS with change in Conners' CPT-3 score

Part B Peak Pruritus NRS scoring as stated above. Conners' CPT-3 scroring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on SP-NRS with change in Conners' CPT-3 score

Part B SP-NRS scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on PROMIS Pediatric Sleep Disturbance with change in Conners' CPT-3 score

Part B PROMIS scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on CDLQI with change in Conners' CPT-3 score

Part B CDLQI scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on HADS with change in Conners' CPT-3 score

Part B HADS scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on IGA with change in Conners' CPT-3 score

Part B IGA scoring as stated above. Conners' CPT-3 scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on EASI with AASP Sensory Sensitivity Summary Score

Part B EASI scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on BSA with AASP Sensory Sensitivity Summary Score

Part B BSA scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on Peak Pruritus NRS with AASP Sensory Sensitivity Summary Score

Part B Peak Pruritus NRS scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on SP-NRS with AASP Sensory Sensitivity Summary Score

Part B SP-NRS scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on PROMIS Pediatric Sleep Disturbance with AASP Sensory Sensitivity Summary Score

Part B PROMIS scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on CDLQI with AASP Sensory Sensitivity Summary Score

Part B CDLQI scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on HADS with AASP Sensory Sensitivity Summary Score

Part B HADS scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16

Correlation of change in AD disease severity based on IGA with AASP Sensory Sensitivity Summary Score

Part B IGA scoring as stated above. AASP scoring as stated above.

Time frame: Up to Week 16